Table 1.
Characteristics of subjects stratified by perfusion type and delay to reperfusion
| Delay in minutes | Fibrinolysis |
Primary PCI |
||||
|---|---|---|---|---|---|---|
| ≤30 n = 1071 | >30 n = 1042 | P-value | ≤90 n = 1626 | >90 n = 1431 | P-value | |
| Sociodemographic | ||||||
| Age in years, median | 60 | 61 | 0.11 | 61 | 61 | 0.47 |
| Women, % | 22 | 28 | 0.001 | 24 | 28 | 0.02 |
| Region, % | ||||||
| Australia/New Zealand/Canada | 26 | 29 | <0.0001 | 4.4 | 6.7 | <0.0001 |
| Europe, % | 54 | 37 | 67 | 53 | ||
| Argentina/Brazil, % | 11 | 22 | 16 | 20 | ||
| USA, % | 8.0 | 12 | 13 | 20 | ||
| Year admitted, % | ||||||
| 2003 | 33 | 32 | 0.86 | 20 | 20 | 0.65 |
| 2004 | 25 | 25 | 23 | 23 | ||
| 2005 | 20 | 19 | 21 | 23 | ||
| 2006 | 12 | 12 | 20 | 20 | ||
| 2007 | 10 | 11 | 15 | 14 | ||
| Medical history, % | ||||||
| Myocardial infarction | 12 | 16 | 0.01 | 11 | 16 | 0.0001 |
| Angiogram (+) CAD | 9.7 | 13 | 0.03 | 12.0 | 16 | 0.003 |
| Prior PCI | 6.9 | 7.5 | 0.61 | 9.6 | 11 | 0.37 |
| Prior CABG | 2.3 | 3.9 | 0.03 | 2.8 | 3.8 | 0.15 |
| Congestive heart failure | 2.5 | 3.3 | 0.36 | 2.5 | 2.2 | 0.63 |
| Peripheral arterial disease | 3.1 | 4.8 | 0.04 | 4.1 | 5.3 | 0.10 |
| Hypertension | 46 | 53 | 0.001 | 46 | 53 | <0.0001 |
| Hyperlipidaemia | 37 | 37 | 0.96 | 39 | 40 | 0.88 |
| Prior stroke/TIA | 3.0 | 4.2 | 0.13 | 2.9 | 4.8 | 0.01 |
| Former/current smoking | 64 | 64 | 0.99 | 63 | 62 | 0.29 |
| Diabetes | 16 | 17 | 0.64 | 16 | 19 | 0.02 |
| Renal insufficiency | 1.8 | 2.7 | 0.18 | 1.9 | 3.6 | 0.005 |
| Presentation characteristics | ||||||
| Admission weight in kg, median | 80 | 78 | 0.42 | 78 | 78 | 0.17 |
| Admission height in cm, median | 170 | 170 | 0.33 | 171 | 170 | 0.04 |
| Body mass index in kg/m2, median | 27 | 27 | 0.56 | 26 | 27 | 0.001 |
| Initial creatinine in mg/dL, median | 1.01 | 1.02 | 0.13 | 1.00 | 1.00 | 0.06 |
| GRACE risk score, median | 134 | 136 | 0.49 | 137 | 138 | 0.45 |
| Killip class (%) | ||||||
| I | 87 | 87 | 0.82 | 86 | 87 | 0.62 |
| II | 9.8 | 9.4 | 9.6 | 9.6 | ||
| III | 2.5 | 2.1 | 1.7 | 2.0 | ||
| IV | 1.0 | 1.2 | 2.3 | 1.8 | ||
| Pulse ≥100 b.p.m., % | 11 | 13 | 0.17 | 12 | 14 | 0.22 |
| Systolic BP <90 mmHg, % | 4.0 | 3.3 | 0.48 | 4.6 | 3.6 | 0.14 |
| >2 h of symptoms before hospital presentation | 40 | 45 | 0.04 | 53 | 53 | 0.86 |
| Patient transferred to hospital no. 2 for reperfusion, % | 23 | 27 | 0.06 | 6.3 | 31 | <0.0001 |
| Prior medicationsa % | ||||||
| Aspirin | 17 | 20 | 0.10 | 16 | 20 | 0.002 |
| ACE-inhibitor | 14 | 17 | 0.05 | 12 | 16 | 0.01 |
| Angiotensin II receptor blocker | 4.1 | 5.1 | 0.30 | 5.5 | 5.3 | 0.87 |
| Beta-blocker | 12 | 17 | 0.001 | 15 | 17 | 0.04 |
| Calcium antagonist | 8.2 | 9.9 | 0.20 | 8.5 | 9.6 | 0.31 |
| Clopidogrel | 2.1 | 1.6 | 0.52 | 3.3 | 3.0 | 0.76 |
| Diuretic | 5.8 | 8.3 | 0.03 | 8.6 | 11 | 0.02 |
| Insulin | 2.8 | 2.6 | 0.79 | 2.7 | 3.9 | 0.05 |
| Nitrate | 3.7 | 6.4 | 0.005 | 3.7 | 4.3 | 0.40 |
| Statin | 14 | 17 | 0.15 | 14 | 17 | 0.01 |
Variables with missing data >1% of total study sample include thrombolyis cohort/PCI cohort: admission weight (n = 239/306), admission height (n = 488/414), admission BMI (n = 524/458), initial creatinine (n = 114/128), GRACE risk score (n = 238/333), Killip class (n = 43/42), pulse (n = 44/106), systolic BP (n = 44/83), prior angiotensin II blocker (n = -/46), prior calcium channel blocker (n = -/41), insulin (n = -/36), nitrate (n = -/34).
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.
aMedications with <2% utilization not listed.